Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer

著者: Clémence Granier, Éléonore De Guillebon, Charlotte Blanc, Hélène Roussel, Cécile Badoual, Elia Colin, Antonin Saldmann, Alain Gey, Stéphane Oudard, Éric Tartour - ESMO Open 2017 被引用: 324

T cells, are more prone to be reactivated by anti-PD-1/PD-L1 monoclonal antibody (mAb). In the future, the challenge will be to rationally combine drugs able to make the tumour microenvironment more permissive to immunotherapy in order to potentiate its clinical activity.